[Intravenous immunoglobulin administration for antibody deficiency (author's transl)].
Seven patients received a total of 23 infusions of a polyvalent largely monomeric and intravenously applicable immunoglobulin preparation (Sandoglobulin). Among them are two with congenital antibody deficiency syndrome. One of them, who has agammaglobulinaemia type Bruton, is still receiving 9 g Sandoglobulin every three months. During the now 40-week period of observation the IgG serum level has remained adequately high, and the patient has had no infection; half-life of the Sandoglobulin is 32.4 days. In the other patient, with recently diagnosed hyper-IgM syndrome, 6 g Sandoglobulin were administered every month or every second month. During an observation period of 44 weeks he had not further infections. The initially much increased IgM serum level (16 g/l) slowly but definitely fell during substitution to 9 g/l at the end of the observation; half-life of Sandoglobulin is 34.1 days. All 23 Sandoglobulin infusions were given without side-effects.
D000293:Adolescent; D000328:Adult; D000361:Agammaglobulinemia / Q000188:drug therapy; D002648:Child; D005260:Female; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007275:Injections, Intravenous; D008297:Male; D013997:Time Factors
D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins
Intravenöse Immunglobulinsubstitution bei Antikörpermangelsyndrom.